Wall Street Fundamentals Releases New In-Depth Stock Reports on CNDO, NKTR, THRX and VNDA
The biotech industry has continued to outpace the broader markets in 2013. The iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) has gained approximately 27.0 percent year-to-date, compared to gains of 14.6 percent and 13.1 percent for the Dow Jones Industrial Average and S&P 500 Index. A favorable regulatory environment has been a major factor in the Industry’s success in 2012 as the U.S. Food and Drug Administration approved 39 new drugs, the highest since 1996. "Genetic information is providing a big opportunity for new drug development," said Fidelity fund manager Rajiv Kaul. "There are exciting new opportunities, but you also need to be careful because most drugs fail."
Coronado Biosciences Inc. (NASDAQ: CNDO) shares traded in the range of $7.87 to $8.05 Thursday before settling to close at $7.99, an increase of 1.01 percent. The stock appears to be facing some resistance at the $8.15 and $8.54 levels with some support at $7.43. Shares of Coronado Biosciences have gained approximately 77.0 percent in 2013.
More information on Coronado Biosciences and access to the free equity report can be found at:
www.WallStreetFundamentals.com/CNDO
Nektar Therapeutics (NASDAQ: NKTR) shares traded in the range of $11.15 to $11.77 Thursday before settling to close at $11.70, an increase of 4.23 percent. The stock appears to have some support at the $8.50 and $8.73 levels. Shares of Nektar Therapeutics have surged approximately 58.0 percent in 2013.
More information on Nektar Therapeutics and access to the free equity report can be found at:
www.WallStreetFundamentals.com/NKTR
Theravance Inc. (NASDAQ: THRX) shares traded in the range of $37.86 to $39.19 Thursday before settling to close at $39.01 a share, an increase of 2.66 percent. The stock appears to be some facing resistance at $41.87 with some support at $36.71. Shares of Hyperion Therapeutics have gained approximately 75 percent in 2013.
More information on Theravance and access to the free equity report can be found at:
www.WallStreetFundamentals.com/THRX
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) shares traded in the range of $7.71 to $8.35 Thursday before settling to close at $8.23, an increase of 6.19 percent. The stock appears to have facing some resistance at $8.89 with some support at $8.03. Shares of Vanda Pharmaceuticals have gained approximately 122 percent in 2013.
More information on Vanda Pharmaceuticals and access to the free equity report can be found at:
www.WallStreetFundamentals.com/VNDA
Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.
Activate your always free membership by signing up at www.WallStreetFundamentals.com today.
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Wall Street Fundamentals
Website: www.WallStreetFundamentals.com
Email: editor@wallstreetfundamentals.com